2022 - Systemic Therapy for Bladder Cancer: Implications for the Urologist Flashcards

1
Q

What types of systemic therapy are now included in the treatment of urothelial carcinoma?

A

In addition to standard chemotherapy, systemic therapy now includes immune checkpoint inhibition, FGFR tyrosine kinase inhibition, and antibody-drug conjugates (ADCs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How many CPIs are FDA approved for urothelial cancer, and what are their names?

A

There are 4 CPIs FDA approved for urothelial cancer: Atezolizumab, Avelumab, Nivolumab, and Pembrolizumab.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What happened to Durvalumab’s approval for urothelial cancer?

A

Durvalumab was previously approved in the second-line (2L) setting, but approval was withdrawn when a phase III trial failed to meet the primary endpoint.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What was the change in approval for Atezolizumab in urothelial cancer treatment?

A

The FDA withdrew Atezolizumab’s second-line (2L) indication after failing to meet superiority over chemotherapy, but it remains approved in the first-line (1L) setting for chemotherapy-ineligible patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the standard first-line (1L) chemotherapy for metastatic or unresectable urothelial cancers?

A

Platinum-based chemotherapy, combined with gemcitabine and cisplatin or carboplatin. Accelerated methotrexate, vincristine, adriamycin, cisplatin is also a 1L choice.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the role of pembrolizumab in BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC)?

A

Pembrolizumab, a PD-1 inhibitor, is FDA-approved for patients with BCG-unresponsive CIS-containing NMIBC, with complete response observed in 40% of patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are ADCs, and how might they be relevant to BCG-unresponsive bladder cancer in the future?

A

ADCs (Antibody-Drug Conjugates) target specific cancer cells, and studies suggest they may become a viable systemic option for patients with BCG-unresponsive bladder cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the main concern for patients with residual muscle invasive and/or lymph node-positive urothelial cancer after surgery?

A

The main concern is the high risk of recurrence, leading to the evaluation of adjuvant immunotherapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the results of using nivolumab as adjuvant therapy, and is there a biomarker requirement?

A

Nivolumab has been FDA approved for a disease-free survival (DFS) rate of 22.9 months, compared to 13.7 months with placebo. There is no biomarker requirement, but a more profound effect was seen in patients with PD-L1+ tumors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What findings were discovered regarding atezolizumab in the postoperative setting?

A

Atezolizumab failed to meet its primary DFS endpoint but demonstrated significant improvement in overall survival in patients with detectable circulating tumor DNA (+ctDNA), leading to a follow-up trial.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is Avelumab, and how is it used in the context of urothelial cancer treatment?

A

Avelumab is a CPI tested and approved for maintenance therapy after achieving a clinical benefit following 1L platinum-based therapy. It’s administered IV every 2 weeks and has improved median overall survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What were the results of the Javelin 100 trial for Avelumab in comparison to observation?

A

The Javelin 100 trial found that Avelumab maintenance led to improved median overall survival of 21.4 versus 14.3 months for observation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What precautions are needed when administering Avelumab, and why?

A

Avelumab carries an increased risk of infusion-related anaphylaxis. Patients are initially premedicated with Benadryl® and acetaminophen, and if no infusion-related events occur, subsequent treatments may be without premedication.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What options are available for patients with disease progression on or after 1L chemotherapy or those who defer avelumab maintenance?

A

For patients with disease progression, CPI therapy, including pembrolizumab, nivolumab, and avelumab, is approved in the 2L (second-line) and beyond setting.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does pembrolizumab stand out among the CPI therapies for use in the 2L and beyond setting?

A

Pembrolizumab was associated with improved overall survival, better tolerance, and quality of life compared to chemotherapy. It carries level 1 evidence, indicating strong support for its effectiveness.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is next-generation sequencing, and what is it used for in the context of urothelial cancer?

A

Next-generation sequencing is a process where DNA is extracted from tissue samples to identify specific patterns like FGFR alterations. It helps in finding therapeutic options for patients with advanced urothelial cancer.

17
Q

How does the presence of FGFR alterations expand therapeutic options in urothelial cancer?

A

FGFR alterations are biomarker targets identified through sequencing. Their presence determines the candidacy for specific treatments like erdafitinib, an FDA-approved therapy for urothelial cancer.

18
Q

What is erdafitinib, and how is it used in treating urothelial cancer with FGFR3 alterations?

A

Erdafitinib is an oral FGFR1-4 tyrosine kinase inhibitor used to treat metastatic urothelial cancer with FGFR3 mutations or fusions. It received accelerated FDA approval in 2019 for patients who had undergone prior chemotherapy.

19
Q

: What were the results of the BLC2001 phase II clinical trial involving erdafitinib, and what are some unique toxicities of this class?

A

The BLC2001 trial showed a 40% objective response rate and 13.8-month median overall survival with erdafitinib. Toxicities include hyponatremia, stomatitis, weakness, hyperphosphatemia, and ocular toxicity.

20
Q

How does hyperphosphatemia relate to FGFR inhibition in urothelial cancer?

A

Hyperphosphatemia is a unique toxicity of FGFR inhibitors like erdafitinib. In the case of infigratinib, another FGFR inhibitor, hyperphosphatemia correlated with clinical benefit, possibly serving as a biomarker of response.

21
Q

What are ADCs, and how do they work in targeting cancer cells?

A

ADCs are Antibody-Drug Conjugates that include an antibody (targeting part), a cytotoxic moiety (destructive part), and a linker sequence. They bind to specific antigens on cancer cells, get inside the cells, and release a toxic substance to destroy them.

22
Q

What are the two FDA-approved ADCs for metastatic bladder cancer, and what do they target?

A

The two FDA-approved ADCs are Enfortumab Vedotin (targets Nectin-4) and Sacituzumab Govitecan (targets Trop-2). Both have shown positive results in clinical trials.

23
Q

What are some common side effects of ADCs like Enfortumab Vedotin and Sacituzumab Govitecan?

A

Common side effects include rash, fatigue, decreased neutrophil count or neutropenia for Enfortumab Vedotin, and neutropenia, leukopenia, anemia, and diarrhea for Sacituzumab Govitecan.

24
Q

What is the THOR trial, and what is its purpose?

A

The THOR trial is a study that aims to answer the sequence question in patients with FGFR3 alterations. It’s randomizing patients to different treatments to find the best order for using certain drugs like erdafinitib or pembrolizumab in the treatment of urothelial carcinoma.

25
Q
A